Related Experiment Video
Updated: Aug 30, 2025

MicroRNA-based Regulation of Picornavirus Tropism
Published on: February 6, 2017
PRC2 Loss and DNMT Inhibition Boost Viral Mimicry in Cancer
Sonia Guil1,2, Manel Esteller1,3,4,5
1Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Catalonia, Spain.
Summary:
In this issue of Cancer Discovery, Patel and colleagues explore the synergistic lethality of PRC2 inactivation and DNMT inhibition in malignant peripheral nerve sheath tumor cells. Reactivation of retrotransposons under this dual control suggests that the viral mimicry response contributes to enhanced cytotoxicity with potential clinical implications. See related article by Patel et al., p. 2120 (5).
Insights
Combining Polycomb repressive complex 2 (PRC2) inactivation with DNA methyltransferase (DNMT) inhibition causes malignant peripheral nerve sheath tumor cells to die. This dual approach reactivates retrotransposons, triggering a viral mimicry response that enhances cancer cell killing.
Area of Science:
- Oncology
- Epigenetics
- Cancer Biology
Background:
- Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive cancers with limited treatment options.
- Epigenetic dysregulation, including alterations in PRC2 and DNMT activity, plays a critical role in MPNST development.
- Understanding the interplay between different epigenetic modifiers is crucial for developing novel therapeutic strategies.
Discussion:
- This study investigates the combined effect of inhibiting PRC2 and DNMTs in MPNST cells.
- The dual inhibition leads to synergistic lethality, indicating a potent anti-cancer effect.
- Reactivation of endogenous retrotransposons is observed under this combined treatment.
Key Insights:
- Simultaneous inactivation of PRC2 and DNMTs induces significant cancer cell death in MPNSTs.
- Retrotransposon reactivation and subsequent viral mimicry response contribute to the observed cytotoxicity.
- This epigenetic targeting strategy offers a promising avenue for MPNST treatment.
Outlook:
- The findings suggest potential clinical implications for combining epigenetic therapies in MPNST treatment.
- Further research is warranted to explore the therapeutic window and efficacy of dual epigenetic inhibition in preclinical models.
- Investigating the precise mechanisms of retrotransposon reactivation and viral mimicry could lead to biomarker development.
Related Concept Videos
Mechanisms of Retrovirus-induced Cancers
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Abnormal Proliferation
MicroRNAs
Experimental RNAi
Viruses with RNA Genomes

